Research programme: nanotechnology-based therapeutics - Cerulean Pharma

Drug Profile

Research programme: nanotechnology-based therapeutics - Cerulean Pharma

Alternative Names: cabazitaxel NDCs; cabazitaxel β-cyclodextrin-PEG copolymer-based nano-particle-drug conjugate; CRLX 288

Latest Information Update: 28 Oct 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cerulean Pharma
  • Class Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Cardiovascular disorders; Inflammation

Most Recent Events

  • 28 Oct 2014 Preclinical development is ongoing in USA
  • 26 Aug 2010 Preclinical pharmacodynamics and adverse events data presented at the 240th American Chemical Society National Meeting (ACS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top